ZURA - NASDAQ

Zura Bio Limited

ZURA·NASDAQ

$3.83

-6.5%

HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$249.36M

EPS-1.0600

P/E Ratio-3.62

Earnings Date08/13/2026

zura

Total Non-Current Assets

Last Annual Value

1.64M

3-Year CAGR

-22%

5-Year CAGR

-59%

10-Year CAGR

-36%

Adjust for Inflation

Zura Bio Limited Competitors Analysis of Total Non-Current Assets

ZURA · NASDAQ

Company	Total Non-Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Zura Bio Limited NASDAQ:ZURA	1.64M	N/A	-58.9%	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	19.41M	-26.6%	70.5%	N/A
Caribou Biosciences, Inc. NASDAQ:CRBU	30.14M	-31.4%	-10.0%	N/A
Neonc Technologies Holdings, Inc. NASDAQ:NTHI	1.43M	N/A	N/A	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	3.13M	0.9%	-1.5%	-19.8%
Entrada Therapeutics, Inc. NASDAQ:TRDA	71.13M	-10.6%	58.4%	N/A
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD	5.29M	215.9%	N/A	N/A
Immuneering Corporation NASDAQ:IMRX	55.74M	60.4%	31.1%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	41.34M	-11.2%	-7.6%	N/A
Sagimet Biosciences Inc. NASDAQ:SGMT	78.00K	2.2%	-26.7%	N/A
Assembly Biosciences, Inc. NASDAQ:ASMB	3.04M	0.1%	-39.3%	-23.5%

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.835, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

HIDDEN

Intrinsic Value

Current Price: $3.835

Related Guides

Blog Categories

Continue your ZURA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.